Dr Ana Arance speaks to ecancer at ESMO 2019 in Barcelona about the Checkmate 067 trial.

This trial looks at nivolumab plus ipilimumab combination therapy in advanced melanoma, and at ESMO 2019 we saw the 5 year survival outcomes.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть